3. (Amended) Method according to claim 1, characterized in that, the matrix is amorphous or partially amorphous.

4. (Amended) Method according to claim 1, characterized in that, the polysaccharide is starch or a derivative thereof.

5. (Amended) Method according to claim 1, characterized in that, the matrix is water-soluble.

6. (Amended) Method according to claim 1, characterized in that, the matrix is a controlled release matrix.

7. (Amended) Method according to claim 1, characterized in that, the release of the active agent of the dosage form substantially follows the lapidus function.

8. (Amended) Method according to claim 1, characterized in that, the release of the active agent of the dosage form may be adjusted over 24 hours or more.

9. (Amended) Method according to claim 1, characterized in that, at least one pharmaceutically active agent is present in the matrix in dissolved, solid or liquid form.

12. (Amended) Dosage form according to claim 10, characterized in that, the matrix is amorphous or partially amorphous.

13. (Amended) Dosage form according to claims 10, characterized in that, the polysaccharide is starch or a derivative thereof.

14. (Amended) Dosage form according to claim 10, characterized in that, the matrix is water-insoluble.

15. (Amended) Dosage form according to claim 10, characterized in that, the matrix is a controlled release matrix.

16. (Amended) Dosage form according to claim 10, characterized in that, the release of the active agent substantially follows the lapidus function.

17. (Amended) Dosage form according to claim 10, characterized in that, the release of the active agent is adjusted over a period of up to 24 hours or longer.

18. (Amended) Dosage form according to claim 10, characterized in that, at least one pharmaceutically active agent is present in the matrix in dissolved, solid or liquid form.

19. (Amended) Use of a dosage form according to claim 10 for producing granulates for tabletting the filling capsules, for further processing using injection molding techniques, as an adjuvant for direct tabletting and/or for producing mono-block pharmaceutical dosage forms.

REMARKS

Initially, the Examiner is requested to examine the claims as amended under PCT Article 34. A clean copy of these claims are attached herewith.

Further, claims 3-9 and 12-19 have been amended herewith to remove the multiple dependencies present in these claims. No new matter has been added by virtue of this amendment.